Gilead Sciences Inc (GILD)
64.78
-0.55
(-0.84%)
USD |
NASDAQ |
May 03, 16:00
64.79
+0.01
(+0.02%)
After-Hours: 20:00
Gilead Sciences SG&A Expense (Quarterly): 1.375B for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 1.375B |
December 31, 2023 | 1.608B |
September 30, 2023 | 1.315B |
June 30, 2023 | 1.849B |
March 31, 2023 | 1.319B |
December 31, 2022 | 2.02B |
September 30, 2022 | 1.213B |
June 30, 2022 | 1.357B |
March 31, 2022 | 1.083B |
December 31, 2021 | 1.65B |
September 30, 2021 | 1.19B |
June 30, 2021 | 1.351B |
March 31, 2021 | 1.055B |
December 31, 2020 | 1.73B |
September 30, 2020 | 1.106B |
June 30, 2020 | 1.239B |
March 31, 2020 | 1.076B |
December 31, 2019 | 1.204B |
September 30, 2019 | 1.052B |
June 30, 2019 | 1.095B |
March 31, 2019 | 1.03B |
December 31, 2018 | 1.131B |
September 30, 2018 | 948.00M |
June 30, 2018 | 980.00M |
March 31, 2018 | 997.00M |
Date | Value |
---|---|
December 31, 2017 | 1.252B |
September 30, 2017 | 879.00M |
June 30, 2017 | 897.00M |
March 31, 2017 | 850.00M |
December 31, 2016 | 992.00M |
September 30, 2016 | 831.00M |
June 30, 2016 | 890.00M |
March 31, 2016 | 685.00M |
December 31, 2015 | 1.066B |
September 30, 2015 | 903.00M |
June 30, 2015 | 812.00M |
March 31, 2015 | 645.00M |
December 31, 2014 | 876.00M |
September 30, 2014 | 945.00M |
June 30, 2014 | 614.00M |
March 31, 2014 | 548.00M |
December 31, 2013 | 512.85M |
September 30, 2013 | 406.86M |
June 30, 2013 | 404.99M |
March 31, 2013 | 374.30M |
December 31, 2012 | 365.79M |
September 30, 2012 | 319.58M |
June 30, 2012 | 332.50M |
March 31, 2012 | 443.12M |
December 31, 2011 | 346.22M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
1.052B
Minimum
Sep 2019
2.02B
Maximum
Dec 2022
1.344B
Average
1.277B
Median
SG&A Expense (Quarterly) Benchmarks
Amgen Inc | 1.808B |
CymaBay Therapeutics Inc (DELISTED) | 19.81M |
Bristol-Myers Squibb Co | 2.367B |
Eli Lilly and Co | 1.836B |
Xilio Therapeutics Inc | 6.394M |